Shire

Pressing for direct negotiations, Takeda adds cash to a meatier $63B bid to buy Shire
Pressing for direct negotiations, Takeda adds cash to a meatier $63B bid to buy Shire
Endpoints
Shire
Takeda
M&A
Flag link:
Allergan will not bid for Shire: Sources
Allergan will not bid for Shire: Sources
CNBC
Allergan
Shire
M&A
Takeda
Flag link:
A bidding war is brewing over $50 billion drugmaker Shire
A bidding war is brewing over $50 billion drugmaker Shire
Business Insider
Shire
Takeda
Allergan
M&A
Flag link:
Takeda makes $61 billion bid for drugmaker Shire: sources
Takeda makes $61 billion bid for drugmaker Shire: sources
Reuters
Takeda
Shire
M&A
Flag link:
The FTC Appeals Shire ViroPharma Dismissal
The FTC Appeals Shire ViroPharma Dismissal
FDA Law Blog
FTC
Shire
ViroPharma
Hatch Waxman Act
Flag link:
How big is too big for a CEO bonus target? Annoyed Shire investors have some ideas
How big is too big for a CEO bonus target? Annoyed Shire investors have some ideas
Fierce Pharma
Shire
Pharma CEOs
executive pay
investors
Flemming Ornskov
Flag link:
Shire's oncology exit weighs on potential Takeda bid
Shire's oncology exit weighs on potential Takeda bid
Biopharma Dive
Shire
oncology
Takeda
M&A
Servier
Flag link:
Servier buys Shire’s oncology unit for $2.4B in the run-up to Takeda’s final buyout offer — if it makes one
Servier buys Shire’s oncology unit for $2.4B in the run-up to Takeda’s final buyout offer — if it makes one
Endpoints
Servier
Shire
Takeda
M&A
oncology
Flag link:
[video]Will Shire Be Bought Out?
[video]Will Shire Be Bought Out?
Motley Fool
Shire
M&A
Takeda
Flag link:
Hopes rise for Shire sale as Takeda CEO discusses case for deal
Hopes rise for Shire sale as Takeda CEO discusses case for deal
NASDAQ.com
Shire
Takeda
Pharma CEOs
M&A
Christophe Weber
Flag link:
Will flush-with-cash Big Pharma beat Takeda to a Shire deal?
Will flush-with-cash Big Pharma beat Takeda to a Shire deal?
Fierce Pharma
Takeda
Shire
M&A
Big Pharma
Flag link:
Teva launches generic version of Shire's top-selling internal medicine
Teva launches generic version of Shire's top-selling internal medicine
Biopharma Dive
Teva Pharmaceutical
generics
Shire
Lialda
ulcerative colitis
Flag link:
Does a $50B-plus Shire buyout even make sense for Takeda? Maybe not
Does a $50B-plus Shire buyout even make sense for Takeda? Maybe not
Endpoints
Shire
Takeda
M&A
Flag link:
Drugmaker Shire soars as Japan's Takeda considers bid
Drugmaker Shire soars as Japan's Takeda considers bid
CNBC
Shire
Takeda
M&A
Flag link:
Court Dismisses FTC’s Citizen Petition Complaint Against Shire
Court Dismisses FTC’s Citizen Petition Complaint Against Shire
RAPS.org
FTC
citizen petitions
Shire
ViroPharma
Flag link:
12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
Endpoints
drug launches
Hemlibra
Roche
Biktarvy
Gilead Sciences
Ozempic
Novo Nordisk
Erleada
JNJ
Shingrix
GSK
Patisiran
Alnylam
Sanofi
Epidiolex
GW Pharma
Aimovig
Amgen
Novartis
lanadelumab
Shire
Elagolix
AbbVie
Steglatro
Pfizer
Merck
Sublocade
Indivior
Flag link:
Shire CEO sees Microsoft tie-up building momentum for faster rare disease diagnosis
Shire CEO sees Microsoft tie-up building momentum for faster rare disease diagnosis
Fierce Pharma
Shire
Pharma CEOs
Microsoft
rare disease
Flemming Ornskov
Flag link:
Ocugen’s Dry Eye Disease Therapy Could Compete with Allergan and Shire
Ocugen’s Dry Eye Disease Therapy Could Compete with Allergan and Shire
Xtalks
Ocugen
dry eye disease
OCU310
Shire
Allergan
Restasis
Xiidra
Flag link:
Top 5 boards for week ending March 10, 2018
Top 5 boards for week ending March 10, 2018
CP Wire
Daiichi Sankyo
Shire
Amgen
Sanofi
AstraZeneca
Flag link:
Shire's HAE candidate boosted by new Phase 3 data
Shire's HAE candidate boosted by new Phase 3 data
Biopharma Dive
Shire
HAE
clinical trials
lanadelumab
Flag link:

Pages